pharma news

Breaking World Pharma News

Genzyme and Isis Report Results of Two Phase 3 Trials of Mipomersen Thursday, 05 August 2010 Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced results of two phase 3 studies of mipomersen in patients who had high cholesterol levels while on maximally tolerated lipid-lowering therapy. Read more...   Shire Proposes to Expand Specialist Gastrointestinal Portfolio Wednesday, 04 August 2010 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that a Luxembourg incorporated wholly-owned subsidiary of Shire plc will launch a voluntary public takeover offer for all the shares in Movetis NV, the Belgium-based European specialty gastrointestinal (GI) company. Read more...   Scientists launch new attack against AIDS Tuesday, 03 August 2010 EU-funded researchers have developed a new defence against infection from the AIDS (acquired immune deficiency syndrome) virus. The pioneering method involves creating a protective shield that restricts the virus from making contact with a susceptible host cell and penetrating the immune system. Read more...   AstraZeneca Second Quarter and Half Year Results 2010 Monday, 02 August 2010 Revenue in the second quarter increased by 1 percent at CER, but was up 3 percent on an actual basis as a result of the positive impact of exchange rate movements. Read more...   Bayer increases sales and earnings in the second quarter Friday, 30 July 2010 Sales of the Bayer Group rose by 14.6 percent in the second quarter, to EUR 9,179 million (Q2 2009: EUR 8,009 million). Adjusted for currency and portfolio effects, business grew by 9.2 percent. Read more...   FDA Grants Priority Review to Cladribine Tablets Thursday, 29 July 2010 Merck KGaA announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Cladribine Tablets as a therapy for relapsing forms of multiple sclerosis (MS). Read more...   Lilly Reports Strong Second-Quarter 2010 Results Wednesday, 28 July 2010 Eli Lilly and Company (NYSE: LLY) announced financial results for the second quarter of 2010. In the second quarter of 2010, worldwide total revenue was $5.749 billion, an increase of 9 percent compared with the second quarter of 2009. Read more...   Sanofi-aventis expresses concern over the approval of another version of enoxaparin sodium Tuesday, 27 July 2010 Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) has reservations on approval by the U.S. Food and Drug Administration (FDA) of another version of enoxaparin sodium. Read more...   Tracking down neuromuscular diseases Monday, 26 July 2010 Neuromuscular diseases (NMDs) are chronic and so far incurable conditions that gradually affect patients' muscles, leading to potentially severe disabilities. Biomedical researchers are busy looking for the diseases' Achilles' heel. Read more...   Sandoz leads the way with first generic version of 'gold standard' anti-thrombotic Lovenox® Monday, 26 July 2010 Sandoz announced the introduction of enoxaparin sodium injection, the first generic version of Lovenox®[1], in the US. Product shipment began immediately following approval by the US Food and Drug Administration (FDA).